VelaVigo Bio has landed its second deal in six months, offloading ex-China rights to a bispecific to Ollin Biosciences for up ...

Click Therapeutics has collected a groundbreaking green light from the FDA for the agency’s first prescription digital ...

After mass layoffs, the FDA has started missing certain deadlines, pushing one biopharma to delay a phase 3 trial and ...

Sanofi is continuing to splash the cash for autoimmune and immunology assets this spring by penning a new deal with ...

Precision Neuroscience has obtained an FDA clearance for a crucial piece of its plans for a full brain-computer interface ...

Evotec’s cost-cutting drive has reached its pipeline. The company axed around 30% of its asset portfolio and offloaded ...

Elevation Oncology has become the second biotech this week to face calls from an activist investor to wind down the company.

Should the approach translate to humans, people with allergies may one day be able to take a vaccine that protects them from dangerous allergic reactions.

Eli Lilly has met its goal of achieving semaglutide-like efficacy with an oral GLP-1 drug. | Eli Lilly has met its goal of ...

Nine months after Johnson & Johnson stepped back from an Addex Therapeutics-partnered epilepsy drug in the wake of a phase 2 ...

The U.S. government continues to end contracts related to the $5 billion Project NextGen initiative, this time terminating ...

Novartis has terminated a phase 2 trial evaluating an investigational ADAMTS-5 inhibitor for patients with osteoarthritis ...